ot available

Not Applicable

• Registration Number: PER-010-10
• Lead Sponsor: BRISTOL MYERS SQUIBB COMPANY,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-21
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

• 1) Informed written consent approved by the IRB / IEC voluntarily signed and dated form in accordance with the guidelines.
2) Invasive breast cancer documented histologically positive for ER + and / or PgR + in 10% of tumor cells or more, with tumor tissue from previous surgery available for analysis of ER / PR, EGFR, PTEN and PIK3CA.
3) Patients must have previously received adjuvant therapy for breast cancer with tamoxifen or exemestane anastraozol. the sequential use of antihormonal agents are allowed.

4) Patients receiving cytotoxic chemotherapy (adjuvant setting in metastatic, or neoadjuvant) therapy must have completed at least 4 weeks before the first dose of randomized study medication.

Exclusion Criteria

• 1) Patients who have received prior hormonal therapy for metastatic disease.
2) Patients who have received prior hormonal therapy for metastatic disease.
3) Symptomatic patients with brain metastases.
4) Patients with signs or symptoms suggestive of understanding

Study & Design

• Study Type: Interventional
• Study Design: Not specified